Predictive Value of Albumin - Bilirubin Score and CRP - Albumin - Lymphocyte Index for HCC Prognosis After Radical Resection

NCT06934070 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 287

Last updated 2025-04-18

No results posted yet for this study

Summary

Evaluate the predictive value of the CALLY index and ALBI grading for the prognosis of patients with hepatocellular carcinoma (HCC) after radical resection, so as to provide a reference for clinical treatment.

Conditions

  • Hepatocellular Carcinoma (HCC)
  • Hepatocellular Carcinoma (HCC) Prognosis

Sponsors & Collaborators

  • Qiang Xu

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-03
Primary Completion
2025-04-03
Completion
2025-04-16

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06934070 on ClinicalTrials.gov